Dr. David Bulmer

Dr Bulmer has unique insight into the development of novel therapeutic approaches targeting nociceptors for the treatment of visceral pain in IBD and IBS, having established research labs within industry (GlaxoSmithKline) and academia (QMUL, University of Cambridge). His work is at the forefront of translational studies on visceral pain examining human visceral afferent activity and working extensively with colonic biopsy samples from patients with gastrointestinal disease.

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.